scholarly journals Expression of CD62P and CD154 in peripheral blood of patients with rheumatoid arthritis and their correlation with clinical indexes

2019 ◽  
Vol 17 ◽  
pp. 205873921882268
Author(s):  
Shiping Qu ◽  
Chunyi Yu ◽  
Qian Xing ◽  
Haisheng Hu ◽  
Haiyan Jin
Keyword(s):  
Rheumatoid Arthritis ◽  
Peripheral Blood ◽  
Healthy Subjects ◽  
Disease Activity Score ◽  
Control Group ◽  
Disease Course ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Pearson Test

The aim of this study is to investigate the expression of CD62P and CD154 in peripheral blood of patients with rheumatoid arthritis (RA) and their correlation with the clinical indexes of RA. A total of 60 RA patients diagnosed and treated in the Department of Rheumatism in our hospital from January to December 2016 were selected as the RA group, and 60 cases of healthy subjects were selected as the control group. CD62P and CD154 levels in peripheral blood were determined by flow cytometry using the FACS Vantage flow cytometer, and the correlation analysis with the clinical indexes of RA patients were conducted. The levels of CD62P and CD154 in the peripheral blood of RA group were 28.75% ± 1.48% and 26.84% ± 1.03%, respectively, which were significantly higher than those of the control group ( P < 0.05). The levels of white blood cell (WBC), platelet (PLT), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), C-reactive protein (CRP), and interleukin (IL)-37 in the RA group were significantly higher than those in the control group ( P < 0.05). Pearson test showed that CD62P and CD154 levels in the peripheral blood in the RA group were positively correlated with serum WBC, PLT, ESR, RF, CRP, IL-37, and disease activity score 28 (DAS28) ( P < 0.05), but not correlated with disease course ( P > 0.05). The expression of CD62P and CD154 in peripheral blood of patients with RA was upregulated, and their expression levels were correlated with the activity of RA and the degree of joint lesion.

scholarly journals DAS28-ESR and DAS28-CRP - are they Interchangeable in Measuring the Activity of Rheumatoid Arthritis in Response to Treatment with Biological Agents?

Folia Medica ◽  
2020 ◽  
Vol 62 (1) ◽  
pp. 46-51
Author(s):  
Tanya K. Shivacheva
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Erythrocyte Sedimentation Rate ◽  
Sedimentation Rate ◽  
Disease Activity Score ◽  
Activity Score ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Low Activity

Introduction: The European League Against Rheumatism updates the recommendations for managing rheumatoid arthritis. Again, it is not specified which DAS28 is there in view (with erythrocyte sedimentation rate or C-reactive protein). &nbsp; Aim: The aim of the study is to check whether Disease Activity Score-28 (erythrocyte sedimentation rate) and Disease Activity Score-28 (C-reactive protein) represent equally the activity of rheumatoid arthritis in the course of treatment with biological agents. &nbsp; Materials and methods: In a retrospective study we analyzed the database of real clinical practice over a 12-month period of biological treatment of rheumatoid arthritis. Disease Activity Score-28 (erythrocyte sedimentation rate) and (C-reactive protein) are compared at the start and at the end of the study. &nbsp; Results: The mean difference between the two variants of disease activity scores at baseline and at the end of the study is significant (p < 0.001). The Disease Activity Score-28 (erythrocyte sedimentation rate) represents a remarkably small proportion of patients with remission and low activity (<3.2) at baseline (18.46%) and at the end of the study (40.51%). Disease Activity Score-28 (C-reactive protein) represents a significantly high proportion of patients in remission and low activity (<3.2) at the end of the study (69.74%). Estimates of activity according to the two variants show significant discrepancy between each other and low level of agreement (kappa = 0.235-0.464). Discrepancies are not related to the type of biological drug (anti-TNF or not). &nbsp; Conclusion: The two DAS28 variants are not interchangeable with the same threshold for low activity in measuring the response to biological therapy.

scholarly journals AB0297 THE LONG-TERM OBSERVATION OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED A BIO-FREE CONDITION WITH ADALIMUMAB.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1447.1-1448
Author(s):  
S. Ito ◽  
S. Sakai ◽  
Y. Kurosawa ◽  
D. Kobayashi ◽  
R. Okabayashi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Sedimentation Rate ◽  
Disease Activity Score ◽  
C Reactive Protein ◽  
Free Condition ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Disease Modifying

Background:Biological disease-modifying antirheumatic drugs (bDMARDs) caused a paradigm shift in the treatment of rheumatoid arthritis (RA). However, their high cost is a burden for patients and the national medical economy.Objectives:To analyze the long-term outcomes of patients with RA who achieved a bio-free condition (BF) with adalimumab (ADA).Methods:We followed 25 patients (male 6, female 19) who discontinued ADA with clinical remission (CR), and one female with a low disease activity (LDA), over 19.4 ±7.8 months of ADA treatment1). At the introduction of ADA, the average age was 51.2 ± 11.9 years old, and the average disease duration was 45.1 ± 48.4 months. The disease activity measured by disease activity score based on C-reactive protein (DAS28-CRP) was defined as follows: CR, <2.3; LDA, 2.3 - 2.7; moderate DA, 2.7 -4.1; and high DA, > 4.1, since the DAS28-CRP tends to be lower than the DAS28-based on the erythrocyte sedimentation rate in Japanese patients2).Results:We lost one patient with a transfer to another hospital. Four patients re-started ADA due to flare (DAS28-CRP>2.7) but achieved CR (in BF) again with the intensification of the treatment (dose increase or initiation of prednisolone [PSL] and/or conventional synthetic [cs] DMARDs such as tacrolimus or iguratimode). The DAS28-CRP significantly decreased from 3.45 ± 1.32 at base line (BL) to 1.55 ± 0.41 (p<0.0001) at BF. It remained 1.59 ± 0.59 (n=25) at 24 months after BF, 1.56 ± 0.39 (n= 20) at 48 months, 1.8 ± 0.7 (n=11) at 60 months. At the last observation, every patient remained in CR up to 84 months (n=2, Figure 1). The modified health assessment questionnaire score significantly decreased from 0.42 ± 0.46 (BL, n=19) to 0.02 ± 0.05 (p<0.002) at BF. It remained 0.03 ± 0.07 (n=19) at 24 months and 0.06 ± 0.14 (n=14) at 48 months, 0.04 ± 0.08 at 60 months (n=9). The PSL dose (mg/day) decreased from 3.2 ± 3.3 (BL) to 2.2 ± 2.8 at BF and 2.04 ± 2.13 (n=25) at 24 months, 1.73 ± 1.9 (n=20) at 48 months, and 1.6 ± 2.3 (n=11) at 60 months, but there were no significant changes. The methotrexate (MTX) dose (mg/week) increased from 10.1 ± 2.9 (BL) to 10.6 ± 2.6 (p< 0.78) at BF, 10.4 ± 3.3 (n=25) at 24 months, 10.7 ± 3.4 (n=20) at 48 months, 10.4 ± 3.1 at 60 months (not significant). The number of csDMARDs significantly increased from 0.8 ± 0.6 (BL) to 1.3 ± 0.9 (p<0.001, at BF), 2.56 ± 0.94 (n=25) at 24 months, 1.6 ± 1.01 (n=20) at 48 mnths, and 1.6 ± 2.3 at 60 months (n=11, Figure 2).Conclusion:BF can be sustained with an adequate dose of MTX and combination of csDMARDs.References:[1]Ito S, et al. An analysis of the biological disease-modifying antirheumatic drug-free condition of adalimumab-treated rheumatoid arthritis patients. Intern Med 58: 511-519, 2019[2]Inoue E, et al. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 66:407-409, 2007.Disclosure of Interests:Satoshi Ito Speakers bureau: Abbvie,Eisai, Shunsuke sakai: None declared, Yoichi Kurosawa: None declared, Daisuke Kobayashi: None declared, Ryo Okabayashi: None declared, Asami Abe: None declared, Hiroshi Otani: None declared, Kiyoshi Nakazono: None declared, Akira Murasawa: None declared, Ichiei Narita: None declared, Hajime Ishikawa: None declared

Sign in / Sign up

Export Citation Format

Share Document